Humana (NYSE:HUM) Issues FY 2024 Earnings Guidance

Humana (NYSE:HUM) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 16.000-16.000 for the period, compared to the consensus earnings per share estimate of 16.250. The company issued revenue guidance of -.

Humana Stock Performance

Shares of NYSE HUM opened at $364.81 on Friday. The stock has a market capitalization of $43.96 billion, a PE ratio of 22.72, a price-to-earnings-growth ratio of 3.16 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The stock has a 50 day moving average price of $367.99 and a 200 day moving average price of $347.34. Humana has a 52 week low of $298.61 and a 52 week high of $530.54.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $8.94 earnings per share. Analysts predict that Humana will post 16.14 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio is currently 22.04%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on HUM shares. Truist Financial boosted their target price on shares of Humana from $355.00 to $400.00 and gave the company a hold rating in a research report on Monday, July 15th. Cantor Fitzgerald restated a neutral rating and set a $395.00 price objective on shares of Humana in a research report on Monday, August 19th. Bank of America lifted their target price on Humana from $342.00 to $376.00 and gave the company a neutral rating in a research report on Monday, May 20th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Humana from $341.00 to $349.00 and gave the stock a hold rating in a report on Friday, August 2nd. Finally, TD Cowen lifted their price target on shares of Humana from $396.00 to $407.00 and gave the company a buy rating in a report on Wednesday, July 24th. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus price target of $398.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.